Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2881835 · 1 trial · 1 indication
Clinically significant adverse effects are treatment emergent adverse events (TEAEs) possibly related to study drug.
| Arm | Type | Description |
|---|---|---|
| LY2881835 | EXPERIMENTAL | One cohort of healthy participants will receive single oral doses of LY2881835 in up to 3 of the 4 periods in Part A (dose escalation: 0.5 milligram (mg), 1.5 mg, subsequent doses determined based on review of safety, tolerability, glycaemic response and available pharmacokinetic (PK) data from the first 2 dose levels). One cohort of participants with Type 2 Diabetes Mellitus (T2DM) will receive single oral doses of LY2881835 in up to 2 of the 3 periods in Part B (dose escalation: starting dose based on review of safety, tolerability, glycaemic response and available PK data from Part A). There is a washout period of at least 5 days between periods (doses). |
| placebo | PLACEBO_COMPARATOR | One cohort of healthy participants will receive a single oral dose of placebo in 1 of the 4 periods in Part A. Another cohort of participants with T2DM will receive a single oral dose of placebo in 1 of the 3 periods in Part B. There is a washout period of at least 5 days between periods (doses). |
| Name | Type | Description |
|---|---|---|
| LY2881835 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: All subjects: * Are a healthy male or a healthy female who cannot become pregnant, or are patients with Type 2 Diabetes Mellitus (T2DM) who are not taking any drugs to lower blood sugar except metformin * Have a body mass index (BMI) of at least 18.5 kilograms per meter squared...
LY2881835 is an investigational small molecule developed by Eli Lilly and Company for the treatment of type 2 diabetes mellitus. It is a Phase 1 clinical candidate and has not been approved for any indication. The compound was studied in a single completed early-stage trial.
LY2881835 targets FFAR1, also known as free fatty acid receptor 1. It acts as an agonist at this receptor. FFAR1 is a G protein-coupled receptor implicated in glucose-dependent insulin secretion, which is the rationale for evaluating the compound in type 2 diabetes.
LY2881835 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound in type 2 diabetes and healthy volunteers.
LY2881835 is in Phase 1 development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The only recorded trial of the compound is completed, and no active trials are ongoing.
LY2881835 was evaluated in one completed Phase 1 trial, NCT01358981, titled A Study of LY2881835 in Healthy People and People With Diabetes. The trial enrolled 18 participants in Singapore, was randomized and placebo controlled, and included healthy volunteers alongside people with type 2 diabetes.